Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bolt Biotherapeutics (BOLT) Accumulated Expenses (2019 - 2025)

Historic Accumulated Expenses for Bolt Biotherapeutics (BOLT) over the last 7 years, with Q3 2025 value amounting to $3.8 million.

  • Bolt Biotherapeutics' Accumulated Expenses fell 6748.26% to $3.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.8 million, marking a year-over-year decrease of 6748.26%. This contributed to the annual value of $9.1 million for FY2024, which is 2725.45% down from last year.
  • Latest data reveals that Bolt Biotherapeutics reported Accumulated Expenses of $3.8 million as of Q3 2025, which was down 6748.26% from $5.4 million recorded in Q2 2025.
  • Over the past 5 years, Bolt Biotherapeutics' Accumulated Expenses peaked at $15.1 million during Q4 2022, and registered a low of $3.8 million during Q3 2025.
  • In the last 5 years, Bolt Biotherapeutics' Accumulated Expenses had a median value of $10.3 million in 2024 and averaged $9.9 million.
  • In the last 5 years, Bolt Biotherapeutics' Accumulated Expenses surged by 8586.22% in 2021 and then crashed by 6748.26% in 2025.
  • Bolt Biotherapeutics' Accumulated Expenses (Quarter) stood at $12.4 million in 2021, then grew by 22.25% to $15.1 million in 2022, then dropped by 17.53% to $12.5 million in 2023, then dropped by 27.25% to $9.1 million in 2024, then plummeted by 57.73% to $3.8 million in 2025.
  • Its last three reported values are $3.8 million in Q3 2025, $5.4 million for Q2 2025, and $6.5 million during Q1 2025.